Nafagrel (BioDeep_00000181530)
human metabolite blood metabolite
代谢物信息卡片
6-[(1H-imidazol-1-yl)methyl]-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid
化学式: C15H16N2O2 (256.1212)
中文名称: 那法格雷
谱图信息:
最多检出来源 Homo sapiens(blood) 50%
分子结构信息
SMILES: C1CC2=C(CC1CN3C=CN=C3)C=CC(=C2)C(=O)O
InChI: InChI=1S/C15H16N2O2/c18-15(19)14-4-3-12-7-11(1-2-13(12)8-14)9-17-6-5-16-10-17/h3-6,8,10-11H,1-2,7,9H2,(H,18,19)
描述信息
C78275 - Agent Affecting Blood or Body Fluid > C1327 - Antiplatelet Agent
D004791 - Enzyme Inhibitors
同义名列表
数据库引用编号
5 个数据库交叉引用编号
- PubChem: 65851
- HMDB: HMDB0255418
- ChEMBL: CHEMBL1189780
- chemspider: 59263
- CAS: 97901-21-8
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
1 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
| 亚细胞结构定位 | 关联基因列表 |
|---|
文献列表
- T Nagao, J Koseki, Y Suzuki, T Nagamatsu. Thromboxane A(2) causes retarded clearance of aggregated protein in glomeruli of nephritic mice.
European journal of pharmacology.
2001 Feb; 413(2-3):271-9. doi:
10.1016/s0014-2999(00)00932-8. [PMID: 11226403] - M Takami, W Tsukada. Effect of DP-1904, a thromboxane synthetase inhibitor, on antigen- and spasmogen-induced bronchoconstriction in rodents.
European journal of pharmacology.
1999 Feb; 366(2-3):253-9. doi:
10.1016/s0014-2999(98)00931-5. [PMID: 10082207] - M Takami, W Tsukada. A possible involvement of thromboxane A2 and peptide leukotrienes in hyperresponsiveness of Sephadex-treated rat lung parenchyma.
Prostaglandins, leukotrienes, and essential fatty acids.
1999 Jan; 60(1):65-71. doi:
10.1054/plef.1998.0009. [PMID: 10319919] - M Takami, W Tsukada. In vitro effect of DP-1904, a novel anti-asthma agent, against antigen-induced constriction and TXB2 release from the isolated guinea-pig lung parenchymal tissue.
Pharmacological research.
1998 Aug; 38(2):141-7. doi:
10.1006/phrs.1998.0346. [PMID: 9721602] - M Takami, W Tsukada. Correlative alteration of thromboxane A2 with antigen-induced bronchoconstriction and the role of platelets as a source of TXA2 synthesis in guinea pigs: effect of DP-1904, an inhibitor of thromboxane synthetase.
Pharmacological research.
1998 Aug; 38(2):133-9. doi:
10.1006/phrs.1998.0345. [PMID: 9721601] - T Yoshida, H Kameda, A Masashi, M Homma, Y Ikeda. Improvement of renal function with selective thromboxane A2 synthetase inhibitor, DP-1904 in lupus nephritis.
Advances in experimental medicine and biology.
1997; 433(?):113-7. doi:
10.1007/978-1-4899-1810-9_23. [PMID: 9561116] - T Nagao, T Nagamatsu, Y Suzuki. Effect of DP-1904, a thromboxane A2 synthase inhibitor, on passive Heymann nephritis in rats.
European journal of pharmacology.
1996 Nov; 316(1):73-80. doi:
10.1016/s0014-2999(96)00662-0. [PMID: 8982653] - N X Zheng, H Sato, I Adachi, I Horikoshi. Pharmacokinetic-pharmacodynamic modelling of DP-1904, a novel thromboxane synthetase inhibitor in rabbits, based on an indirect response model.
European journal of drug metabolism and pharmacokinetics.
1996 Oct; 21(4):285-93. doi:
10.1007/bf03189729. [PMID: 9074892] - T Yoshida, H Kameda, Y Ichikawa, T Tojo, M Homma. Improvement of renal function with a selective thromboxane A2 synthetase inhibitor, DP-1904, in lupus nephritis.
The Journal of rheumatology.
1996 Oct; 23(10):1719-24. doi:
NULL. [PMID: 8895147] - T Yoshida, Y Ichikawa, T Tojo, M Homma. Abnormal prostanoid metabolism in lupus nephritis and the effects of a thromboxane A2 synthetase inhibitor, DP-1904.
Lupus.
1996 Apr; 5(2):129-38. doi:
10.1177/096120339600500208. [PMID: 8743126] - T Nagao, M Ito, T Nagamatsu, Y Suzuki. Effect of DP-1904, a thromboxane A2 synthetase inhibitor, on crescentic nephritis in rats.
European journal of pharmacology.
1994 Jul; 259(3):233-42. doi:
10.1016/0014-2999(94)90649-1. [PMID: 7982449] - A Ohnishi, T Ishizaki, H Echizen, K Yasuda, H Fujiwara, T Tanaka. Effects of a sustained thromboxane synthase inhibition on exercise-induced changes in eicosanoid formation, catecholamine concentration, and platelet aggregation in humans.
Clinical pharmacology and therapeutics.
1992 Apr; 51(4):454-64. doi:
10.1038/clpt.1992.46. [PMID: 1563215] - H Masumura, S Kunitada, K Irie, S Ashida, Y Abe. A thromboxane A2 synthetase inhibitor retards hypertensive rat diabetic nephropathy.
European journal of pharmacology.
1992 Jan; 210(2):163-72. doi:
10.1016/0014-2999(92)90667-s. [PMID: 1350991] - H Masumura, S Kunitada, K Irie, S Ashida, Y Abe. A thromboxane A2 synthase inhibitor, DP-1904, prevents rat renal injury.
European journal of pharmacology.
1991 Feb; 193(3):321-7. doi:
10.1016/0014-2999(91)90146-h. [PMID: 2055246] - A Tsuchida, T Miura, T Ogawa, T Iwamoto, K Shimamoto, O Iimura. Inhibition of thromboxane A2 synthetase failed to limit myocardial infarct size in a rabbit ischemia-reperfusion model.
Japanese circulation journal.
1991 Feb; 55(2):174-83. doi:
10.1253/jcj.55.174. [PMID: 2020088] - M Tanaka, K Ono, H Hakusui, T Takegoshi, Y Watanabe, M Kanao. Identification of DP-1904 and its ester glucuronide in human urine and determination of their enantiomeric compositions by high-performance liquid chromatography with optical activity and ultraviolet detection.
Drug metabolism and disposition: the biological fate of chemicals.
1990 Sep; 18(5):698-703. doi:
NULL. [PMID: 1981723] - M Tanaka, K Ono, H Hakusui, T Takegoshi, T Shiozawa, T Suzuki, S Nii, H Shibata. The pharmacokinetics and pharmacodynamics of a new thromboxane synthetase inhibitor, 6-(1-imidazolylmethyl)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid (DP-1904) in man after repeated oral doses.
The Journal of pharmacy and pharmacology.
1990 Jul; 42(7):491-5. doi:
10.1111/j.2042-7158.1990.tb06602.x. [PMID: 1980290] - M Tanaka, K Ono, H Hakusui, T Takegoshi, T Shiozawa, S Nii, H Shibata. Disposition and effect of the new thromboxane synthetase inhibitor 6-(1-imidazolylmethyl)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid in man.
Arzneimittel-Forschung.
1990 Jun; 40(6):712-5. doi:
NULL. [PMID: 2397009] - I Toda, A Nozaki, K Kawakubo, Y Murakawa, H Inoue, N Yoshimoto, T Sugimoto. Effects of a thromboxane A2 synthetase inhibitor on ventricular fibrillation threshold during coronary artery occlusion and reperfusion.
Japanese heart journal.
1990 Jan; 31(1):87-97. doi:
10.1536/ihj.31.87. [PMID: 2335849] - M Tanaka, K Ono, T Takegoshi, T Shiozawa, T Suzuki, S Nii, H Shibata. The pharmacokinetics and pharmacodynamics of a new thromboxane synthetase inhibitor, 6-(1-imidazolylmethyl)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid (DP-1904), in man after single oral administration.
The Journal of pharmacy and pharmacology.
1989 Oct; 41(10):680-4. doi:
10.1111/j.2042-7158.1989.tb06340.x. [PMID: 2575144] - M Tanaka, K Ono, T Takegoshi. Determination of the thromboxane synthetase inhibitor 6-(1-imidazolylmethyl)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid (DP-1904) in human plasma and urine using solid-phase extraction and high-performance liquid chromatography.
Journal of chromatography.
1988 Apr; 426(1):111-9. doi:
10.1016/s0378-4347(00)81932-5. [PMID: 3384863]
